Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure (NCT03730649) | Clinical Trial Compass
Active — Not RecruitingEarly Phase 1
Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure
United States12 participantsStarted 2019-10-09
Plain-language summary
The study is to compare the expression of both keratin 16 and 17 before and after application of sulforaphane on both photoprotected and photoexposed area, and to determine whether these findings alter skin aging as well as skin response to ultraviolet (UV) and visible light exposure.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Participants must be over the age of 18 years old with healthy skin or moderate degree of photoaging/intrinsic aging;
* Must be healthy enough to undergo skin biopsy, light irradiation, and other study procedures in the opinion of the investigator;
* Must be willing to comply with the requirements of the protocol;
* Must have the ability to understand and communicate with the investigator;
* Participant must provide informed consent.
Exclusion Criteria:
* Subjects who are unable to provide informed consent;
* Subject with significant medical history or current skin diseases that the investigator feels is not safe for study participation;
* Subjects who have been treated with systemic retinoids or steroids within the past month prior to entry to the study;
* Subjects who have been treated with topical steroids, retinoids or other topical drugs used within 2 weeks prior to entry to the study;
* Recently treated or current skin diseases that would affect clinical evaluation and biopsy;
* Subjects with a known allergy to broccoli.
* Presence or suspicion of bleeding disorder or diathesis which would complicate biopsy.
* Subjects with a history of excessive scar or keloid formation in the past 10 years.
* Pregnant or nursing subjects (self-reported).
* Subjects with known allergy to anesthetics used.
* Patients with history of investigational drug use in the 30 days prior to entry into the study.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
keratin 16 presence as determined by immunofluorescence assay
Timeframe: Up to 6 months
2
keratin 17 presence as determined by immunofluorescence assay
Timeframe: Up to 6 months
3
keratin 16 fold change as determined by Reverse Transcription Polymerase Chain Reaction (RT-PCR)